NCT03869697已完成1 期
A Phase I Study Evaluating the Safety, Tolerability, Efficacy, and Pharmacokinetics of SCB-313, a Fully-Human TRAIL-Trimer Fusion Protein, for the Treatment of Malignant Pleural Effusions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 5
- 试验地点
- 4
- 主要终点
- Occurrence of DLT
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, preliminary efficacy, and PK/PD of SCB-313 (recombinant human TRAIL-Trimer fusion protein) administered once via intrapleural injection (SAD) and once daily over 2 to 3 days (MAD)for the treatment of cancer patients with symptomatic malignant pleural effusions requiring drainage.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed cancer of any primary tumor type.
- •Malignant pleural effusion causing respiratory symptoms requiring drainage that is histologically or cytologically confirmed; or pleural effusion with radiologically proven pleural malignancy as diagnosed in normal clinical practice on thoracic computed tomography in the absence of histocytological or cytological proof.
- •Eastern Cooperative Oncology Group (ECOG) performance status: 0 to
- •Patients with an ECOG performance status of 3 may be included if the Investigator determines that removal of pleural fluid would improve their performance status to 2 or better.
- •Life expectancy of at least 8 weeks.
- •Age ≥18 years.
- •Adequate hematologic function, defined as:
- •Platelet count ≥75,000/μL;
- •Prothrombin time and activated partial thromboplastin time ≤1.5 times the upper limit of normal (ULN);
- •Absolute neutrophil count ≥1,500 μL;
- •Hemoglobin ≥8 g/dL (transfusion and erythropoietic agents are allowed). In case there is existence of active bleeding or other persistent condition of either increased destruction or impaired production of erythrocytes, which may require repeated transfusion or erythropoietic treatment, the eligibility must be discussed with the Sponsor on a case-by-case basis prior to randomization).
- •Adequate renal function, defined as creatinine clearance >40 mL/minute.
- •Adequate liver function, defined as:
- •Aspartate aminotransferase and alanine aminotransferase ≤2.0 times ULN;
- •Bilirubin ≤2.0 times ULN, unless patient has known Gilbert's syndrome.
- •Female patients of childbearing potential (excluding women who have undergone surgical sterilization or are menopausal, defined as no menstrual periods for 1 year or more without any other medical reasons) are eligible if they have negative serum pregnancy test result 7 days before the first dose of SCB-313 and are willing to use an effective method of birth control/contraception to prevent pregnancy until 6 months after discontinuation of SCB-
- •Both men and women of reproductive potential must agree to use effective contraception during the study and for 6 months after discontinuation of SCB-
- •Note: Contraceptive methods that are considered highly effective areas follows: total abstinence, intrauterine device, double barrier method (such as condom plus diaphragm with spermicide), contraceptive implant, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices, or injections with prolonged release), or vasectomized partner with confirmed azoospermia.
- •Willing to attend follow-up visits on Days 10, and 21 after the first study drug administration.
排除标准
- •Significantly loculated pleural effusions not amenable to drainage or patient is unlikely to benefit from intrapleural therapy.
- •Concurrent use of any investigational product (IP) or investigational medicine within 28 days before Day 1 of study drug administration.
- •Radiotherapy outside the chest field within 2 weeks, or radical radiotherapy to pleural or lung lesions within 8 weeks prior to enrollment (Note: palliative radiotherapy to the chest is allowed).
- •Start a new systemic anticancer therapy, including chemotherapy, targeted therapy, immuno-oncology (I-O) therapy regimen, within 28 days before Day 1 of study drug administration or during DLT observation period.
- •Acute or chronic infection (such as tuberculosis) requiring antiviral or intravenous antibiotics within 2 weeks prior to enrollment.
- •Clinical unstable or uncontrolled concomitant hematologic, cardiovascular, pulmonary, hepatic, renal, pancreatic, or endocrine diseases.
- •History of gross hemoptysis (>2.5 mL).
- •Residual adverse events (AEs) > Grade 2 from previous treatment.
- •Evidence or suspicion of relevant psychiatric impairment, including alcohol or recreational drug abuse.
- •Myocardial infarction within 6 months prior to treatment and/or prior diagnoses of congestive heart failure (New York Heart Association Class III or IV), unstable angina, unstable cardiac arrhythmia requiring medication, and/or long QT syndrome or QT/QTc interval >480 msec at Baseline.
- •Uncontrolled hypertension defined as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg confirmed upon repeated measures (note: no more than 3 repeated measures allowed).
- •Major surgery (open procedures) within 4 weeks prior to enrollment.
- •Patient with ileus within 30 days prior to Screening.
- •Positive serology test for human immunodeficiency virus type 1 and/or 2, or known history of other immunodeficiency disease.
- •Live vaccine within 2 weeks prior to enrollment.
- •Scheduled participation in another clinical study involving an investigational product or device during the DLT observation period of this study.
- •Previous treatment with a TRAIL-based therapy or death receptor 4/5 agonist therapy.
- •Known or suspected hypersensitivity to any component of SCB-
- •Any further condition which, in the opinion of the Investigator, may result in undue risk of the patient by participating in the present study.
- •Untreated central nervous system metastatic disease, leptomeningeal disease, or cord compression.
研究组 & 干预措施
SCB-313
Experimental
Cohorts in SAD phase: 5 mg, 10mg, 20mg, 40mg, 80 mg. Cohort in MAD phase: biological effective dose determined from SAD phase. 1 intrapleural injection of SCB-313 on Day 1 for the SAD cohorts, and 3 intrapleural injections of SCB-313 on Days 1, 2 and 3 for the MAD cohort.
干预措施: SCB-313 (Drug)
结局指标
主要结局
Occurrence of DLT
时间窗: Up to 21 days after start of treatment
Occurrence of dose limiting toxicity (DLT)
次要结局
- Carcinoembryonic antigen (CEA)(Up to 21 days after start of treatment)
- Pleural effusion drainage-free rate at Day 21(At Day 21 after start of treatment)
- SAEs or TEAEs(Up to 21 days after start of treatment)
- Immunogenicity(Up to 21 days after start of treatment)
- Pleural effusion response rate at Day 21(At Day 21 after start of treatment)
- The changes in effusion volume and flow rate after SCB-313 treatment , and at next drainage over the baseline daily effusion flow rate.(Up to 6 months after start of treatment)
- Blood oxygen levels(Up to 21 days after start of treatment)
- Overall survival(Up to 6 months after start of treatment)
- Pharmacokinetics (Cmax)(Up to 4 days after start of treatment)
- Pharmacokinetics(Cmax/D)(Up to 4 days after start of treatment)
- Pharmacokinetics(Tmax)(Up to 4 days after start of treatment)
- Pharmacokinetics ([AUC]0-24)(Up to 4 days after start of treatment)
- Pharmacokinetics (AUC0-24/D)(Up to 4 days after start of treatment)
- Pharmacokinetics ((AUC0-last))(Up to 4 days after start of treatment)
- Pharmacokinetics (Ctrough)(Up to 4 days after start of treatment)
- Amount of drug in pleural effusion(Up to 4 days after start of treatment)
- Pharmacokinetics (AUC 0-inf)(Up to 4 days after start of treatment)
- Pharmacokinetics (AUC0-inf/D)(Up to 4 days after start of treatment)
- Pharmacokinetics (t1/2)(Up to 4 days after start of treatment)
- Pharmacokinetics (CL/F serum only)(Up to 4 days after start of treatment)
- Pharmacokinetics (Vz/F serum only)(Up to 4 days after start of treatment)
- Pharmacokinetics (λz)(Up to 4 days after start of treatment)
- Tumor response(Up to 6 months after start of treatment)
- TRAIL resistance(Baseline)
- CA-125(Up to 21 days after start of treatment)
- CA-19-9(Up to 21 days after start of treatment)
- Changes in 24-hour urine volume(Up to 4 days after start of treatment)
- Changes in GFR(Up to 4 days after start of treatment)
- Changes in tumor cell count in pleural effusion samples(Up to 4 days after start of treatment)
- Caspase-cleaved CK18(Up to 10 days after start of treatment)
- KRAS mutation(Baseline)
- MMR defects(Baseline)
- Bcl2 overexpression(Baseline)
研究者
研究点 (4)
Loading locations...
相似试验
尚未招募
1 期
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of HLX35 in Combination With HLX10 in Patients With Advanced or Metastatic Solid TumorsSolid Tumor, AdultNCT05442996Shanghai Henlius Biotech30
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of a Single Dose of NBI-98854 in Subjects With Mild,Moderate, or Severe Hepatic InsufficiencySafety, Tolerability, and PK of NBI-98854 in Hepatically Impaired SubjectsNCT01916993Neurocrine Biosciences24
Unknown
1 期
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast CancerChemotherapy-induced NeutropeniaNCT02725606Jiangsu T-Mab Biopharma Co.,Ltd30
已完成
1 期
: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid TumorsAdvanced Solid TumorNCT03903705Hutchmed348
Unknown
1 期
A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis PatientsRheumatoid ArthritisNCT04179513Genor Biopharma Co., Ltd.24